TOP STORY
Study Identifies Promising Treatment for Aggressive Lymphoma
New research illustrates that some patients with transformed lymphoma showed “remarkable” response to lenalidomide, an oral drug with few side effects. [Press release from Mayo Clinic discussing research to be presented at the American Society of Clinical Oncology Annual Meeting]
|
|
CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal)
LABORATORY RESEARCH
PTPN2
in T Cell Acute Lymphoblastic Leukemia” target=”_blank” href=”http://www.nature.com/ng/journal/v42/n6/full/ng.587.html” conversion=”false” alias=”C02 Deletion of the Protein Tyrosine Phosphatase Gene PTPN2 in T Cell Acute Lymphoblastic Leukemia”>Deletion of the Protein Tyrosine Phosphatase Gene PTPN2 in T Cell Acute Lymphoblastic Leukemia
In this work, researchers describe the identification of focal deletions of PTPN2 in human T cell acute lymphoblastic leukemia. [Nat Genet]
ATP-Binding Cassette Transporters and HDL Suppress Hematopoietic Stem Cell Proliferation
The findings indicate that ATP-binding cassette transporters ABCA1 and ABCG1, and HDL inhibit the proliferation of hematopoietic stem and multipotential progenitor cells and connect expansion of these populations with leukocytosis and accelerated atherosclerosis. [Science]
Accelerated Leukemogenesis by Truncated CBF(Beta)-SMMHC Defective in High-Affinity Binding with RUNX1
Here, researchers report that the type I CBF(beta)-SMMHC protein binds RUNX1 inefficiently. [Cancer Cell]
The Galactocerebrosidase Enzyme Contributes to the Maintenance of a Functional Hematopoietic Stem Cell Niche
The findings indicate that the lysosomal galactocerebrosidase enzyme, defective in Globoid Cell Leukodystrophy, is involved in the maintenance of a functional hematopoietic stem/progenitor cell niche by contributing to the control of the intracellular content of key sphingolipids. [Blood]
Stat5a Serine 725 and 779 Phosphorylation is a Prerequisite for Hematopoietic Transformation
Mutations or fusions of oncogenic tyrosine kinases often result in constitutive Stat5 activation. Researchers have modeled persistent Stat5 activity by using an oncogenic Stat5a variant. [Blood]
A Conceptual Framework for the Identification of Candidate Drugs and Drug Targets in Acute Promyelocytic Leukemia
In this study, researchers used publicly available microarray data sets and identified signatures of genes dysregulated in acute promyelocytic leukemia (APL) by comparison of gene expression profiles of APL cells and normal promyelocytes representing the same stage of differentiation. [Leukemia]
Ubiquitin Conjugase UBCH8 Targets Active FMS-Like Tyrosine Kinase 3 for Proteasomal Degradation
Researchers report here that treatment of acute myeloid leukemia cells with the histone deacetylase inhibitor LBH589 induces the ubiquitin-conjugating enzyme UBCH8 and degradation of constitutively active mutant FMS-like tyrosine kinase 3. [Leukemia]
Reversal of Chemotherapy-Induced Leukopenia Using Granulocyte Macrophage Colony-Stimulating Factor Promotes Bone Metastasis That Can Be Blocked with Osteoclast Inhibitors
Researchers evaluated the ability of granulocyte macrophage colony-stimulating factor to promote bone metastases of breast cancer or prostate cancer in a mouse model of chemotherapy-induced leukopenia. [Cancer Res]
CLINICAL RESEARCH
Site and Timing of First Relapse in Stage III Melanoma Patients: Implications for Follow-Up Guidelines
Clinical records of stage III patients with no evidence of disease seen at Memorial Sloan-Kettering Cancer Center between 1992 and 2004, who ultimately relapsed, were reviewed retrospectively to evaluate date of first relapse, time to first relapse, method of first relapse detection, and survival. [J Clin Oncol]
Immune Monitoring with iTAg(TM) MHC Tetramers for Prediction of Recurrent or Persistent Cytomegalovirus (CMV) Infection or Disease in Allogeneic Hematopoietic Stem Cell Transplant (HCT) Recipients: A Prospective Multicenter Study
Researchers evaluated the use of HLA Class I tetramers in monitoring CMV-specific T cell recovery to predict patients at risk for CMV-related complications. [Blood]
|
|
INDUSTRY NEWS
CytRx Initiates Phase II Clinical Trial with Bafetinib in B Cell Chronic Lymphocytic Leukemia
CytRx Corporation announced initiation of a Phase II proof-of-concept clinical trial to evaluate the preliminary efficacy and safety of its oncology drug candidate bafetinib in patients with high-risk B cell chronic lymphocytic leukemia. [CytRx Corporation Press Release]
OHSU Joins Forces With UO, Harvard to Accelerate Fanconi Anemia Research
Oregon Health & Science University is partnering with the University of Oregon and Harvard Medical School to expedite basic science research into new and existing drugs and compounds that may prevent the complications associated with Fanconi anemia. [Oregon Health & Science University Press Release]
Rockwell Medical to Present Phase IIb Data at XLVII ERA-EDTA Congress in Munich, Germany June 25-28, 2010
Rockwell Medical announced that Phase IIb data for its lead drug candidate Soluble Ferric Pyrophosphate have been accepted for presentation at the XLVII European Renal Association – European Dialysis and Transplant Association Congress, organized in collaboration with the Deutsche Gesellschaft fur Nephrologie in Munich, Germany, June 25-28, 2010. [Rockwell Medical Press Release]
Seventh Sense, Rox Anderson and Bob Langer Startup, Seeks to Collect Blood With No Pain
Seventh Sense Biosystems wants to remove some of the hassle, expense, and pain of collecting blood for medical tests. The secretive startup has recently begun talks with major healthcare companies about its technology, which includes a device for collecting blood samples that almost anyone ought to be able to use without causing pain. [Xconomy]
|
|
POLICY NEWS
Treasury Releases New Guidance for Tax Credit in Affordable Care Act to Support Groundbreaking Biomedical Research
The U.S. Department of the Treasury announced the guidelines for applying for the new Therapeutic Discovery Project Program created by the Affordable Care Act. [Department of the Treasury, United States]
Third Time’s a Charm for COMPETES Bill
By a vote of 262 to 150, legislators authorized $84 billion for research, education, and innovation programs over the next 5 years at the National Science Foundation, the Department of Energy, and two Department of Commerce agencies – NOAA and NIST under the America COMPETES Reauthorization Act (HR 5116). [House of Representatives, United States]
Democrats: FDA Should Be Able to Recall Drugs
House Democrats repeatedly called for federal regulators to be given the authority to recall drugs. Pending legislation would grant that power to the Food and Drug Administration (FDA) for food, but not for drugs. [House of Representatives, United States]
Congress Considers Synthetic Biology Risks, Benefits
Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, said that the government is moving quickly to bring synthetic biology under review by two existing panels that have done a good job of monitoring cutting-edge research in the past. [House of Representatives Committee on Energy and Commerce, United States]
Last Hurrah from National Academies Stem Cell Committee
Even though the National Institutes of Health issued stem cell guidelines last year, there’s still a need for guidelines for research that remains off-limits for U.S. government-funded labs. [National Academies’ National Research Council and Institute of Medicine, United States]
NIH Set to Tighten Financial Rules for Researchers
After a wave of financial scandals over the past few years involving biomedical researchers, the U.S. National Institutes of Health (NIH) proposed far-reaching changes that would lead to tighter oversight of agency-funded extramural investigators and their institutions. [National Institutes of Health, United States]
Request for Information (RFI) on the NIH Plan to Develop the Genetic Testing Registry (NOT-OD-10-101) [National Institutes of Health, United States]
Administrative Supplements to Advance Special Translational Research Acceleration Projects on Immune Response Modifiers Currently Funded by the National Cancer Institute (NCI) (NOT-CA-10-025) [National Institutes of Health, United States]
AABB Donor History Questionnaire Documents [National Institutes of Health, United States]
Exceptions and Alternative Procedures Approved Under 21 CFR 640.120 [Food and Drug Administration, United States]
|
|
EVENTS
International Society for Stem Cell Research (ISSCR) 8th Annual Meeting
June 16-19, 2010
San Francisco, United States
XXXIst International Congress of the International Society of Blood Transfusion (ISBT) in joint cooperation with the 43rd Congress of the German Society for Transfusion Medicine and Immunohematology (DGTI)
June 26-July 1, 2010
Berlin, Germany
Translational Cancer Medicine 2010 – USA
July 11-14, 2010
San Francisco, United States
United Kingdom National Stem Cell Network (UKNSCN) Annual Scientific Conference
July 12-14, 2010
Nottingham, United Kingdom
Select Biosciences 3rd Annual Stem Cells Europe Conference
August 24-25, 2010
Edinburgh, Scotland
Select Biosciences 2nd Annual World Biobanking Summit
August 24-25, 2010
Edinburgh, Scotland
Select Biosciences Inaugural Cellular Therapy Summit
August 24-25, 2010
Edinburgh, Scotland
The European Molecular Biology Organization (EMBO) Meeting 2010
September 4-7, 2010
Barcelona, Spain
International Society for Cellular Therapy (ISCT) – Europe 2nd Regional Meeting
September 11-14, 2010
Belgirate, Italy
Stem Cells USA & Regenerative Medicine Congress 2010
September 13-15, 2010
Philadelphia, United States
Society for Hematology and Stem Cells (ISEH) 2010 Meeting
September 15-18, 2010
Melbourne, Australia
Stem Cells and Regeneration
October 3-9, 2010
Woods Hole, United States
American Association of Blood Banks (AABB) Annual Meeting 2010
October 9-12, 2010
Baltimore, United States
Fraunhofer Life Science Symposium Leipzig 2010
October 29-30, 2010
Leipzig, Germany
52nd American Society of Hematology (ASH) Annual Meeting and Exposition
December 4-7, 2010
Orlando, United States
Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.
JOB OPPORTUNITIES
Senior Scientist – Magnetic Cell Separation (STEMCELL Technologies)
Business Development Manager Europe – Cell Therapy Products (Pall Corporation)
Sr. Product Support and Training Specialist (CardianBCT)
Manager/Sr. Manager, Therapeutic Cell Solutions, Process Development (Lonza)
Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Cell Therapy News.
Visit here to post your career opportunities.
Have we missed an important article or publication in Hematopoiesis News? Click here to submit!
Comments or Suggestions? Email info@connexoncreative.com with your feedback.
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
